TLDR Sharps pivots from medtech to crypto giant with $400M Solana treasury. Sharps Technology bets big on Solana, partners with Coinbase for custody From syringes to Solana: Sharps unveils $400M crypto treasury strategy. Sharps joins Coinbase to manage $400M Solana trove, redefining its future. Sharps Technology transforms into a blockchain treasury powerhouse. Sharps Technology, Inc.(STSS) [...] The post Sharps Technology (STSS) Stock: Coinbase Partnership Fuels $400M Solana Treasury Expansion appeared first on CoinCentral.TLDR Sharps pivots from medtech to crypto giant with $400M Solana treasury. Sharps Technology bets big on Solana, partners with Coinbase for custody From syringes to Solana: Sharps unveils $400M crypto treasury strategy. Sharps joins Coinbase to manage $400M Solana trove, redefining its future. Sharps Technology transforms into a blockchain treasury powerhouse. Sharps Technology, Inc.(STSS) [...] The post Sharps Technology (STSS) Stock: Coinbase Partnership Fuels $400M Solana Treasury Expansion appeared first on CoinCentral.

Sharps Technology (STSS) Stock: Coinbase Partnership Fuels $400M Solana Treasury Expansion

2025/10/10 03:10
3 min read

TLDR

  • Sharps pivots from medtech to crypto giant with $400M Solana treasury.
  • Sharps Technology bets big on Solana, partners with Coinbase for custody
  • From syringes to Solana: Sharps unveils $400M crypto treasury strategy.
  • Sharps joins Coinbase to manage $400M Solana trove, redefining its future.
  • Sharps Technology transforms into a blockchain treasury powerhouse.

Sharps Technology, Inc.(STSS) shares began the trading day with volatility but later stabilized near $6.68, recording a slight decline of 0.15%.

Sharps Technology (STSS)

The company captured attention with a bold treasury move into digital assets. The announcement of a strategic collaboration with Coinbase significantly reinforced this transition.

The new partnership with Coinbase supports Sharps Technology’s ongoing strategy to build a major Solana (SOL) digital asset treasury. It aims to leverage Coinbase’s infrastructure and trading services to manage the growing crypto holdings. This decision marks a milestone in its shift from medical sales to blockchain-backed financial management.

Sharps Technology signals its confidence in long-term blockchain adoption and commitment to regulated digital finance infrastructure. The company’s market activities now combine traditional capital markets with the potential of decentralized finance. While its stock saw minor fluctuations, the business direction reflected a strong, calculated pivot.

Sharps Acquires Over 2 Million SOL for Treasury

Sharps Technology has acquired more than 2 million Solana tokens, currently valued at over $400 million. The tokens were secured through capital raised via a private placement disclosed in August. At the current SOL price above $210, the treasury value underlines the scale of the firm’s strategy.

The shift began with a $400 million raise aimed at creating one of the largest Solana-based digital treasuries. The company’s goal involves generating on-chain yields by deploying SOL tokens within the growing decentralized finance space. The treasury activity represents a sharp contrast to its original business model in medical devices.

Newly appointed Chief Investment Officer Alice Zhang emphasized the timing and institutional interest in Solana as key drivers. Her team brings experience in institutional crypto platforms, aligning with the firm’s ambitious digital pivot. As adoption of Solana accelerates, the treasury model may offer new financial advantages for the company.

Coinbase Prime Powers Institutional-Grade Treasury Management

Coinbase will provide Sharps Technology with its Prime platform for custody and trading services. These services include secure token storage and access to over-the-counter liquidity for large-scale trades. Sharps will benefit from Coinbase’s regulatory compliance, operational security, and market access.

Coinbase Prime’s infrastructure is designed to handle large crypto treasuries for public companies and institutions. For Sharps, this ensures safety, transparency, and efficiency in managing a high-value digital portfolio. This partnership also supports the growth of the Solana ecosystem by linking traditional capital with decentralized technology.

The collaboration also aligns with the company’s broader ambition to support global adoption of digital assets. Working with Coinbase enhances credibility and bridges the gap between traditional investors and blockchain-based finance. Sharps Technology positions itself as a hybrid entity, blending real-world capital markets with Web3 innovation.

 

The post Sharps Technology (STSS) Stock: Coinbase Partnership Fuels $400M Solana Treasury Expansion appeared first on CoinCentral.

Market Opportunity
FUTURECOIN Logo
FUTURECOIN Price(FUTURE)
$0.07263
$0.07263$0.07263
-2.92%
USD
FUTURECOIN (FUTURE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26